Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast ...

Targeted axillary dissection (TAD) emerged as the optimal minimally invasive technique, demonstrating superior diagnostic accuracy over other approaches in patients with node-positive breast cancer ...

Response-guided axillary treatment using an approach known as the MARI protocol can safely spare many women with node-positive breast cancer from axillary lymph node dissection (ALND) after ...

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment. Targeted axillary dissection is used for ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Nearly 10 years of follow-up from a large clinical trial have confirmed that axillary dissection is not necessary in patients with early breast cancer. Nearly 10 years of follow-up from a large ...

Patients with lymph node-positive breast cancer may still avoid extensive axillary surgery if they have clear nodes after systemic therapy, data from a prospective registry showed. Patients with clear ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

MIAMI BEACH -- The surgical dogma favoring axillary dissection in breast cancer continues to give way to more selective data-driven strategies that allow more women to avoid axillary surgery, an ...